Vasculitis & polymyalgia rheumatica
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
Primary result · Remission at weeks 36 and 48 (adjusted %)Result — go to the resultDifference 3 percentage points 95% CI −13 to 18Authors' conclusion
Benralizumab was noninferior to mepolizumab for the induction of remission in patients with relapsing or refractory EGPA.
Study context
- Population
- Adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) receiving standard care
- Participants
- 140 adults
- Comparison
- Benralizumab 30 mg vs mepolizumab 300 mg SC every 4 weeks for 52 weeks
- Benralizumabn = 70
- Mepolizumabn = 70reference
- Primary endpoint
- Remission at weeks 36 and 48
- Follow-up
- Weeks 36 and 48
Methodological detailsmulticentre, double-blind, phase 3, active-controlled, non-inferiority
- Multicentre
- Double-blind
- Phase 3
- Active-controlled
- Non-inferiority
Primary result
Remission at weeks 36 and 48 (adjusted %)
Difference
3 percentage points
95% CI −13 to 18
P = 0.73 for superiority
By group
Benralizumabvs Mepolizumab
difference 3 percentage points (95% CI −13 to 18); P = 0.73 for superiority
As reported in the abstract
Secondary outcomes
Complete withdrawal of oral GC · weeks 48 through 52
Blood eosinophil count, baseline
Blood eosinophil count, week 52
Accrued duration of remission and time to first relapse
- Similar in the two groups
Safety
Adverse events
Serious adverse events
Original publication
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. Published 23 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →